Mascarenhas D
Celtrix Pharmaceuticals, Santa Clara, CA 95054-1815, USA.
Nat Biotechnol. 1998 Dec;16(13):1371-2. doi: 10.1038/4357.
Circumventing existing patents may be a shortcut to getting your recombinant protein to market.
规避现有专利可能是将你的重组蛋白推向市场的一条捷径。